UK's Groundbreaking Gene Therapy Treats 2 Blood Diseases

For thousands living with debilitating blood disorders, a revolutionary treatment is finally reaching patients after years of waiting.

Casgevy, the world's first approved Crispr gene-editing therapy, is now treating patients in the UK with sickle cell disease and β-thalassaemia. Both conditions stem from genetic errors that affect haemoglobin, the protein that carries oxygen through our blood.

For people with sickle cell disease, misshapen blood cells clump together and block vessels, causing extreme pain. The condition affects 17,000 people in the UK, making it the country's biggest genetic blood disorder.

β-thalassaemia causes dangerously low haemoglobin levels, forcing about 1,000 UK patients to receive blood transfusions every three to five weeks. Both conditions have had few treatment options until now.

Casgevy works by editing a specific gene using Crispr technology, allowing the body to produce foetal haemoglobin instead of the faulty adult version. This simple genetic switch makes all the difference.

Clinical trials showed stunning results. Among sickle cell patients, 97% experienced no serious pain episodes for an entire year after treatment. For β-thalassaemia patients, 93% didn't need a transfusion for at least 12 months.

The journey to approval wasn't easy. The treatment's £1.65 million price tag initially stopped approval, with health officials questioning whether it offered good value.

But patient testimony changed everything. People shared how these diseases affected their daily lives, and in September 2024, the therapy finally got the green light for β-thalassaemia patients over 12. Approval for severe sickle cell cases followed in early 2025.

The Ripple Effect

While only about 50 eligible patients were expected to receive treatment in the first year, the approval represents something bigger. It proves that gene-editing therapies can move from laboratory promise to real-world treatment.

The predominantly affects people of African and Caribbean heritage, along with other people of color and mixed heritage communities. John James, chief executive of the Sickle Cell Society, notes that for a "rare disorder," it's actually a really big condition affecting thousands.

Experts are now collecting long-term data through a managed access program. This information will help refine the treatment and potentially expand access to more patients who've been waiting for a solution.

The approval shows that patient voices matter in medical decisions. When the community spoke up about their daily struggles, decision-makers listened and acted.

Casgevy isn't just treating individual patients; it's opening doors for an entirely new class of genetic medicines that could transform how we treat inherited diseases.